In a report released yesterday, Derek Archila from Stifel Nicolaus maintained a Hold rating on Aimmune Therapeutics (AIMT), with a price target of $30. The company’s shares closed last Monday at $24.67.
“We think the latter could put a damper on the “bolus effect” more optimistic investors are expecting at launch. As we have long said, we expect Palforzia to be approved, however; we remain less convicted that it will achieve out year consensus sales forecasts which we think remain aggressive. Maintain Hold. It was clear the panel felt a REMS is needed; mgmt indicated to us its discussions with the FDA are ongoing to finalize what the REMS will ultimately look like. Unsurprisingly, Palforzia’s safety concerns were the focus of the panel as the risk of side effects, including anaphylaxis, was higher in the treatment group relative to placebo.”
According to TipRanks.com, Archila has currently no stars on a ranking scale of 0-5 stars, with an average return of -9.6% and a 29.5% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals Inc, and NGM Biopharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aimmune Therapeutics with a $61.33 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $36.12 and a one-year low of $16.95. Currently, Aimmune Therapeutics has an average volume of 710.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.
Read More on AIMT: